Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Handa Oncology LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of prosecution activity suggests a focused portfolio in this specific sector. Practitioners should observe that the company's current USPTO engagement is limited to a single technical channel.
The busiest examiner for the company is TRAN, ERIC, who is responsible for 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner handles the entirety of the company's current workload before the USPTO. The prosecution strategy is presently consolidated under this individual and 1 distinct art unit, which simplifies the tracking of deadlines and examiner interactions. This centralized approach means that the company's immediate patent outcomes are dependent on the review process of this examiner. This concentration of resources requires a precise understanding of the examiner's previous rulings and preferences to ensure successful patent issuance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 1 | 70.8% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18931783 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | TRAN, ERIC | 155d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18931783 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | TRAN, ERIC | 1629 | Other | Non-Final OA | 155d overdue | Pending | Oct 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial